Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis

• Published in: Thoracic cancer 2022-01, Vol.13 (1), p.31-37
• Main Authors: Yang, Yifan, Wang, Liming, Li, Xu, Zhang, Shuai, Yu, Jiangyong, Nie, Xin, Liu, Wenbo, Wu, Xiaonan, Zhang, Ping, Li, Yi, Li, Ailing, Ai, Bin
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; bevacizumab; Bevacizumab - therapeutic use; Bias; cancer; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Chemotherapy; Drug Therapy, Combination; EGFR‐TKI; ErbB Receptors - antagonists & inhibitors; Humans; Lung cancer; Lung Neoplasms - drug therapy; Medical prognosis; Meta-analysis; Monoclonal antibodies; Mutation; NSCLC; Original; Progression-Free Survival; Protein Kinase Inhibitors - therapeutic use; Randomized Controlled Trials as Topic; Response rates; Targeted cancer therapy; Tumors; Vascular endothelial growth factor
• ISSN: 1759-7706; 1759-7714
• DOI: 10.1111/1759-7714.14214

Background The aim of this study was to estimate the efficacy and safety of bevacizumab combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in advanced non‐small cell lung cancer (NSCLC) patients. Methods We searched randomized controlled trials (RCTs) on bevacizumab combined with EGFR TKIs in the NSCLC Cochrane Library, Web of Science, PubMed and Embase. The data were extracted and assessed according to the Cochrane Handbook. We calculated the hazard ratio (HR), risk ratio (RR), and confidence interval (CI), and accomplished this meta‐analysis with Stata 14 software. Results Of 1301 articles scanned, five articles were involved in this meta‐analysis. We determined that compared with using EGFR TKIs alone, combination treatment significantly prolongs progression‐free survival (PFS) (HR = 0.61, 95% CI = 0.52–0.70; p